| Dr Hailen Mak, MD | |
|
1101 Welch Rd, Suite A-2, Palo Alto, CA 94304-1924 | |
| (650) 322-3847 | |
| (650) 322-3249 |
| Full Name | Dr Hailen Mak |
|---|---|
| Gender | Female |
| Speciality | Allergy & Immunology - Allergy |
| Location | 1101 Welch Rd, Palo Alto, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225083868 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207KA0200X | Allergy & Immunology - Allergy | G29821 (California) | Primary |
| Entity Name | Lpch Medical Group Div Of Lucile |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
An international research group has successfully tested the use of a new type of porous material for the efficient delivery of key molecules to transplanted cells derived from stem cells. These results can lead to improvements in the way stem cell-based neurodegenerative diseases are treated.
Omnicell, Inc., a leading global provider of system solutions to acute healthcare facilities, today announced results for its first quarter ended March 31, 2010.
Spirogen Limited and Celtic Therapeutics Holdings LP announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute of the USA, and is now actively recruiting patients for treatment.
Since the beginning of 2020, labs from all around the world are sequencing the material from positive tests of people affected by COVID-19 and then depositing sequences mostly to three points of collection: GenBank, COG-UK, and GISAID.
› Verified 3 days ago
| Entity Name | Welch Pasteur Allergy Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578571154 PECOS PAC ID: 7911009220 Enrollment ID: O20070216000213 |
News Archive
An international research group has successfully tested the use of a new type of porous material for the efficient delivery of key molecules to transplanted cells derived from stem cells. These results can lead to improvements in the way stem cell-based neurodegenerative diseases are treated.
Omnicell, Inc., a leading global provider of system solutions to acute healthcare facilities, today announced results for its first quarter ended March 31, 2010.
Spirogen Limited and Celtic Therapeutics Holdings LP announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute of the USA, and is now actively recruiting patients for treatment.
Since the beginning of 2020, labs from all around the world are sequencing the material from positive tests of people affected by COVID-19 and then depositing sequences mostly to three points of collection: GenBank, COG-UK, and GISAID.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hailen Mak, MD 1510 Oakcreek Dr, #405, Palo Alto, CA 94304-2033 Ph: (650) 322-3847 | Dr Hailen Mak, MD 1101 Welch Rd, Suite A-2, Palo Alto, CA 94304-1924 Ph: (650) 322-3847 |
News Archive
An international research group has successfully tested the use of a new type of porous material for the efficient delivery of key molecules to transplanted cells derived from stem cells. These results can lead to improvements in the way stem cell-based neurodegenerative diseases are treated.
Omnicell, Inc., a leading global provider of system solutions to acute healthcare facilities, today announced results for its first quarter ended March 31, 2010.
Spirogen Limited and Celtic Therapeutics Holdings LP announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute of the USA, and is now actively recruiting patients for treatment.
Since the beginning of 2020, labs from all around the world are sequencing the material from positive tests of people affected by COVID-19 and then depositing sequences mostly to three points of collection: GenBank, COG-UK, and GISAID.
› Verified 3 days ago
Muhammad Hassan Bashir, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Richard Barry Moss, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-498-5710 | |
Sean Austin Mcghee, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Steven Barry Machtinger, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Robert Bocian, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-321-4121 | |
Sayantani Bhattacharya Sindher, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 |